SCHEDULE: Cormorant Asset Management Boosts VYNE Stake
Beneficial Ownership Report
Cormorant Asset Management and Bihua Chen report a combined 8.23% beneficial ownership stake in VYNE Therapeutics Inc., holding 1,370,938 shares.
Summary
- Cormorant Asset Management, LP and Bihua Chen collectively hold 1,370,938 shares of VYNE Therapeutics Inc. Common Stock.
- This represents 8.23% of the outstanding Common Stock of VYNE Therapeutics Inc.
- The beneficial ownership is shared, with both voting and dispositive power over all reported shares.
- The percentage is calculated based on 16,664,892 shares outstanding as of May 1, 2025, as reported in VYNE Therapeutics Inc.'s Form 10-Q for the quarter ended March 31, 2025.
- Cormorant Global Healthcare Master Fund, LP, a Cormorant Fund, holds more than 5% of the shares and has the right to receive dividends or proceeds from their sale.
Sentiment
Score: 5
Explanation: A Schedule 13G filing is a factual disclosure of beneficial ownership and does not inherently convey positive or negative sentiment regarding the company's performance or prospects. It simply reports a significant stake held by an institutional investor.
Positives
- A significant institutional investor, Cormorant Asset Management, LP, and its managing member, Bihua Chen, hold a substantial stake, indicating potential confidence in the company.
Negatives
- NA
Risks
- NA
Future Outlook
NA
Industry Context
NA
Comparison to Industry Standards
- NA
Legal Proceedings
- NA
Related Party Transactions
- NA
Stakeholder Impact
- Shareholders: Provides transparency regarding significant institutional ownership, which can influence market perception and trading activity.
Next Steps
- NA
Key Dates
| Date | Description |
|---|---|
| 2025-03-31 | End of quarterly period for which VYNE Therapeutics Inc. filed its Form 10-Q. |
| 2025-05-01 | Date as of which 16,664,892 shares of VYNE Therapeutics Inc. Common Stock were outstanding. |
| 2025-05-08 | Date VYNE Therapeutics Inc. filed its Quarterly Report on Form 10-Q with the SEC. |
| 2025-06-30 | Date of event which requires filing of this statement (Amendment No. 3). |
| 2025-08-14 | Date of filing of this Schedule 13G Amendment No. 3. |
Keywords
VYNE Therapeutics, Cormorant Asset Management, Bihua Chen, Schedule 13G, beneficial ownership, common stock, institutional investment, healthcare, biotechnology
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.